$MDGL insider trading
Over the last 12 months, Madrigal Pharmaceuticals insiders reported no purchases and 26 sales totaling $78.1M across SEC Form 4 filings. 54% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $78.1M 26 events
- Events · 12m
- 26 Form 4 filings, grouped
- Insiders · 12m
- 9 distinct reporters
- 10b5-1 share
- 54% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Sibold William JohnPresident and CEO · O·D | ▼ Sale | 11,583 | $538.65 | $6.2M | -5.5% | plan · 24 tranches |
| Aug 17, 2026 | Kelley Shannon TGeneral Counsel · O | ▼ Sale | 664 | $514.97 | $342K | -5.5% | — |
| Jul 20, 2026 | Sibold William JohnPresident and CEO · O·D | ▼ Sale | 2,500 | $547.3 | $1.4M | -1.2% | 10 tranches |
| Jun 1, 2026 | Soergel DavidChief Medical Officer · O | ▼ Sale | 1,042 | $495.74 | $517K | -9.4% | plan |
| Mar 6, 2026 | Dier MardiEVP and CFO · O | ▼ Sale | 1,982 | $430.87 | $854K | -13.7% | plan · 12 tranches |
| Mar 6, 2026 | Sibold William JohnPresident and CEO · O·D | ▼ Sale | 1,663 | $431.94 | $718K | -1% | — |
| Mar 6, 2026 | Kelley Shannon TGeneral Counsel · O | ▼ Sale | 360 | $431.94 | $155K | -2.9% | — |
| Mar 6, 2026 | Huntsman CaroleChief Commercial Officer · O | ▼ Sale | 419 | $431.94 | $181K | -3.2% | — |
| Mar 6, 2026 | Taub RebeccaD | ▼ Sale | 491 | $431.94 | $212K | -0.1% | — |
| Mar 2, 2026 | Dier MardiEVP and CFO · O | ▼ Sale | 1,183 | $427.21 | $505K | -11.3% | — |
| Jan 26, 2026 | Huntsman CaroleChief Commercial Officer · O | ▼ Sale | 910 | $493.78 | $449K | -9.1% | plan · 2 tranches |
| Jan 26, 2026 | Sibold William JohnPresident and CEO · O·D | ▼ Sale | 1,577 | $492.42 | $777K | -1.1% | — |
| Jan 26, 2026 | Taub RebeccaD | ▼ Sale | 647 | $492.42 | $319K | -0.1% | — |
| Jan 20, 2026 | Kelley Shannon TGeneral Counsel · O | ▼ Sale | 692 | $497.36 | $344K | -7.5% | plan · 2 tranches |
| Jan 20, 2026 | Taub RebeccaD | ▼ Sale | 2,238 | $490.77 | $1.1M | -0.5% | — |
| Jan 9, 2026 | FRIEDMAN PAUL AD | ▼ Sale | 280 | $551.24 | $154K | -0.1% | plan |
| Jan 9, 2026 | FRIEDMAN PAUL AD | ▼ Sale | 24,520 | $522.39 | $12.8M | -11.6% | plan · 28 tranches |
| Jan 9, 2026 | Taub RebeccaD | ▼ Sale | 240 | $550.33 | $132K | -0.1% | plan · 2 tranches |
| Jan 9, 2026 | Taub RebeccaD | ▼ Sale | 18,410 | $522.4 | $9.6M | -3.9% | plan · 28 tranches |
| Dec 10, 2025 | FRIEDMAN PAUL AD | ▼ Sale | 24,800 | $552.18 | $13.7M | -11.7% | plan · 9 tranches |
| Dec 10, 2025 | Taub RebeccaD | ▼ Sale | 18,650 | $552.15 | $10.3M | -3.9% | plan · 9 tranches |
| Dec 4, 2025 | Sibold William JohnPresident and CEO · O·D | ▼ Sale | 2,400 | $575.34 | $1.4M | -1.6% | — |
| Dec 2, 2025 | Dier MardiEVP and CFO · O | ▼ Sale | 4,173 | $578.34 | $2.4M | -28.6% | plan · 15 tranches |
| Nov 21, 2025 | Huntsman CaroleChief Commercial Officer · O | ▼ Sale | 1,958 | $553.11 | $1.1M | -16.3% | plan · 11 tranches |
| Nov 13, 2025 | Levy Richard SD | ▼ Sale | 8,500 | $520.96 | $4.4M | -28.6% | plan · 14 tranches |
| Nov 5, 2025 | BATE KENNETHD | ▼ Sale | 16,575 | $484.3 | $8.0M | -86.3% | 11 tranches |
| Sep 9, 2025 | Sibold William JohnPresident and CEO · O·D | ▼ Sale | 7,279 | $445.63 | $3.2M | -6.6% | — |
| Aug 21, 2025 | Sibold William JohnPresident and CEO · O·D | ▼ Sale | 7,616 | $400.18 | $3.0M | -6.5% | plan · 2 tranches |
| Aug 20, 2025 | BAKER BROS. ADVISORS LPD | ▲ Buy | 97,065 | $380.58 | $36.9M | +5.2% | 26 tranches · indirect |
| Aug 18, 2025 | BAKER BROS. ADVISORS LPD | ▲ Buy | 68,618 | $364.04 | $25.0M | +3.8% | 28 tranches · indirect |
| Aug 18, 2025 | Kelley Shannon TGeneral Counsel · O | ▼ Sale | 1,304 | $367.81 | $480K | -12.4% | plan · 8 tranches |
| Aug 15, 2025 | BATE KENNETHD | ▼ Sale | 10,000 | $365.2 | $3.7M | -79.2% | 6 tranches |
| Aug 13, 2025 | FRIEDMAN PAUL AD | ▼ Sale | 129,172 | $370.24 | $47.8M | -40.8% | plan · 17 tranches |
| Aug 12, 2025 | Taub RebeccaD | ▼ Sale | 46,463 | $355.32 | $16.5M | -9.2% | plan · 12 tranches |
| Aug 12, 2025 | FRIEDMAN PAUL AD | ▼ Sale | 46,808 | $355.31 | $16.6M | -20% | plan · 12 tranches |
Every $MDGL filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Madrigal Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $MDGL feed.